Page last updated: 2024-11-04

cholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cholic acid is a primary bile acid synthesized in the liver from cholesterol. It plays a crucial role in the digestion and absorption of fats by forming micelles, which solubilize lipids in the aqueous environment of the gut. Cholic acid is also involved in the elimination of cholesterol from the body. Research on cholic acid focuses on its role in lipid metabolism, its potential therapeutic applications in conditions like gallstones and obesity, and its contribution to the development of liver diseases. Studies investigate its synthesis pathways, interactions with intestinal bacteria, and its impact on the gut microbiome.'

Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID221493
CHEMBL ID205596
CHEBI ID16359
SCHEMBL ID27461
MeSH IDM0029428
PubMed CID303
SCHEMBL ID171402
MeSH IDM0029428

Synonyms (193)

Synonym
smr000112165
MLS001066422
BIDD:PXR0196
kolbam
gtpl609
orphacolreg
cholalic acid
nsc6135
cholan-24-oic acid,7,12-trihydroxy-, (3.alpha.,5.beta.,7.alpha.,12.alpha.)-
5.beta.-cholan-24-oic acid,7.alpha.,12.alpha.-trihydroxy-
colalin
cholalin
3.alpha.,12.alpha.-trihydroxy-5.beta.-cholanic acid
nsc-6135
cholsaeure
(3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid
3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid
CHEBI:16359 ,
brn 2822009
einecs 201-337-8
ccris 1626
c24h40o5
3-alpha,7-alpha,12-alpha-trihydroxycholansaeure [german]
colalin (van)
cholsaeure [german]
SPECTRUM5_002005
CHD ,
sodium cholate
(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid
(3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-trihydroxycholan-24-oic acid sodium salt
LMST04010001
hsdb 982
5beta-cholanic acid-3alpha,7alpha,12alpha-triol 5beta-cholic acid
3alpha,7alpha,12alpha-trihydroxy-5beta-cholanoic acid
3alpha,7alpha,12alpha-trihydroxy-beta-cholanic acid
5beta-cholan-24-oic acid, 3alpha,7alpha,12alpha-trihydroxy-
3,7,12-trihydroxycholanic acid
cholic acid, 5beta-
cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9ci)
17beta-[1-methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol
3alpha,7alpha,12alpha-trihydroxycholanic acid
3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholan-24-oic acid
17-beta-(1-methyl-3-carboxypropyl)etiocholane-3alpha,7alpha,12alpha-triol
cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-
cholic acid (8ci)
cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)-
3,7,12-trihydroxy-cholan-24-oic acid (3-alpha,5-beta,7-alpha,12-alpha)
5beta-cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7ci)
3,7,12-trihydroxycholan-24-oic acid, (3alpha,5beta,7alpha,12alpha)-
3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate
361-09-1
(r)-4-((3r,5s,7r,8r,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
cholicacid
chembl205596 ,
bdbm21680
(4r)-4-[(1s,2s,5r,7s,9r,10r,11s,14r,15r,16s)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid
C00695
3alpha,7alpha,12alpha-trihydroxy-5beta-cholanic acid
CHOLATE ,
81-25-4
3alpha,7alpha,12alpha-trihydroxy-5beta-cholanate
cholic acid
cholic acid, from ox or sheep bile, >=98%
DB02659
cholbam
(3alpha,5beta,7alpha,8x,12alpha)-3,7,12-trihydroxycholan-24-oic acid
MLS002207051
BMSE000650
(3alpha,5beta,7alpha,8xi,12alpha)-3,7,12-trihydroxycholan-24-oic acid
STK801993
AKOS005622502
3-alpha,7-alpha,12-alpha-trihydroxycholansaeure
unii-g1jo7801ae
ec 201-337-8
cholic acid [usan]
4-10-00-02072 (beilstein handbook reference)
g1jo7801ae ,
A830252
(r)-4-((3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
HMS2268L18
S3742
4-((1s,2s,7s,11s,16s,5r,9r,10r,14r,15r)-5,9,16-trihydroxy-2,15-dimethyltetracy clo[8.7.0.0<2,7>.0<11,15>]heptadec-14-yl)pentanoic acid
C-5900
ursodeoxycholic acid impurity b [ep impurity]
cholic acid [ep impurity]
cholic acid [who-dd]
cholic acid [orange book]
cholic acid [hsdb]
cholic acid [fcc]
cholan-24-oic acid, 3,7,12-trihydroxy-, (3-.alpha.,5-.beta.,7-.alpha.,12-.alpha.)-
cholic acid [mi]
orphacol
cholic acid [jan]
cholic acid [ema epar]
cholic acid [usp-rs]
BP-30084
3alpha, 7alpha, 12alpha-trihydroxy-5beta-cholanoic acid
3alpha, 7alpha, 12alpha-trihydroxy-5beta-cholanic acid
BBL029799
SCHEMBL27461
3a,7a,12a-trihydroxy-5a-cholanic acid
cholbam (tn)
cholic acid (usan)
D10699
5.beta.-cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-
17.beta.-(1-methyl-3-carboxypropyl)etiocholane-3.alpha.,7.alpha.,12.alpha.-triol
3-.alpha.,7-.alpha.,12-.alpha.-trihydroxy-5-.beta.-cholan-24-oic acid
3-.alpha.,7-.alpha.,12-.alpha.-trihydroxycholansaeure
5.beta.-cholic acid
3,7,12-trihydroxy-cholan-24-oic acid, (3.alpha.,5.beta.,7.alpha.,12.alpha.)-
cholan-24-oic acid, 3,7,12-trihydroxy-, (3a,5b,7a,12a)-
mfcd00003672
DTXSID6040660 ,
cholic acid, european pharmacopoeia (ep) reference standard
cholic acid, 500 mug/ml in methanol, certified reference material
sr-01000765698
SR-01000765698-4
cholic acid, united states pharmacopeia (usp) reference standard
HY-N0324
CS-6608
AS-69849
(4r)-4-[(1r,3as,3br,4r,5as,7r,9as,9bs,11s,11ar)-4,7,11-trihydroxy-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-1-yl]pentanoic acid
cholic acid, vetec(tm) reagent grade, 98%
5b-cholate
cholalate
5b-cholanic acid-3a,7a,12a-triol
17b-[1-methyl-3-carboxypropyl]etiocholane-3a,7a,12a-triol
3a,7a,12a-trihydroxy-5b-cholanic acid
3a,7a,12a-trihydroxy-b-cholanic acid
3a,7a,12a-trihydroxy-5b-cholan-24-oate
3a,7a,12a-trihydroxy-5b-cholanoate
3a,7a,12a-trihydroxy-beta-cholanic acid
3a,7a,12a-trihydroxy-b-cholanate
3a,7a,12a-trihydroxycholanic acid
3a,7a,12a-trihydroxy-5b-cholan-24-oic acid
3a,7a,12a-trihydroxy-5b-cholanoic acid
3a,7a,12a-trihydroxycholanate
5b-cholic acid
3a,7a,12a-trihydroxy-5b-cholanate
3a,7a,12a-trihydroxy-beta-cholanate
cholic acid, british pharmacopoeia (bp) reference standard
129874-08-4
(3alpha,5beta,7alpha,8alpha,12alpha,14beta,17alpha)-3,7,12-trihydroxycholan-24-oic acid
5beta-cholanic acid-3alpha,7alpha,12alpha-triol
cholic acid (sodium)
10321-98-9
Q287415
(4r)-4-((3r,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
cholic-acid
CCG-268746
NCGC00142384-03
terpenes and terpenoids
cholsa currencyure
3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid (cholic acid)
4-[(3r,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid
EN300-6766788
(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoicacid
orphacol®
dtxcid4020660
ursodeoxycholic acid impurity b (ep impurity)
cholic acid (ep impurity)
cholic acid (usp-rs)
Z1954806455
HMS1678A18
LS-15079
cholan-24-oic acid, 3,7,12-trihydroxy-, (3.alpha.,5.beta.,7.alpha.,12.alpha.)-
3,7,12-trihydroxycholan-24-oic acid
4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
NCI60_003386
nsc657947
OPREA1_388172
MLS001240272
4-(3,7,12-trihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid
smr000768690
AKOS000511084
L001220
FT-0665024
HMS2233J24
FT-0675749
FT-0621983
8008-63-7
HMS3371N03
SCHEMBL171402
BHQCQFFYRZLCQQ-UHFFFAOYSA-N
3.alpha.,7.alpha.,12.alpha.-trihydroxy-5.beta.-cholanic acid
choleinsaure
J-015612
SY012968
(3b,5b,7a,12a)-3,7,12-trihydroxy-cholan-24-oic acid
BCP31486
ursodeoxycholic acid ep impurity d;7-epicholic acid;ursocholate
gall
DTXSID201334862

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The relative toxic potential of the drug congeners (CsG greater than CsA greater than CsH = CsF = CsA/M17) correlated well with the degree of their accumulation in the hepatocytes during exposure to equimolar drug concentrations."( In vitro toxicity assessment of cyclosporin A and its analogs in a primary rat hepatocyte culture model.
Boelsterli, UA; Bouis, P; Brouillard, JF; Donatsch, P, 1988
)
0.27
"5 or 5% activated charcoal, which presumably enhances elimination of the toxic agent from the organism."( Prevention of TCDD toxicity in laboratory rodents by addition of charcoal or cholic acids to chow.
Coccia, P; Croci, T; Manara, L, 1984
)
0.27
" MO at 50 cm pressure and Ch at both 40 and 50 cm pressure were significantly more toxic than saline."( Toxic effects of intrahepatic reflux of monooctanoin in a canine model.
Gadacz, TR; Sharp, KW, 1984
)
0.27
" Contraceptive efficacy was assessed by a pregnancy test, while safety was evaluated by performing gynecological examinations as well as reporting adverse events."( A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge.
Colin, P; Creatsas, G; Drouin, J; Guerrero, E; Guilbert, E; Lemieux, L; Serfaty, D; Suissa, S, 2001
)
0.31
" Finally, the safety profile was very good, with no clinically significant evidence of local or systemic adverse reactions."( A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge.
Colin, P; Creatsas, G; Drouin, J; Guerrero, E; Guilbert, E; Lemieux, L; Serfaty, D; Suissa, S, 2001
)
0.31
"The new Protectaid sponge is a safe and effective non-hormonal contraceptive method for women."( A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge.
Colin, P; Creatsas, G; Drouin, J; Guerrero, E; Guilbert, E; Lemieux, L; Serfaty, D; Suissa, S, 2001
)
0.31
"The toxic effects of two forms of the new vaginal contraceptive sponge, Protectaid, in the cervical and vaginal tissues were studied."( Safety and tolerability of the new contraceptive sponge Protectaid.
Colin, P; Creatsas, G; Elsheikh, A, 2002
)
0.31
" To elucidate the toxic effect of snake bile acids on rats, a synthetic bile acid mixture was prepared mimicking the bile acid composition of a snake Naja naja atra bile juice."( Bile acid composition in snake bile juice and toxicity of snake bile acids to rats.
Deng, JF; Hwang, DF; Liau, MY; Noguchi, T; Wang, DY; Wu, ML; Yeh, YH, 2003
)
0.32
"Oral CA therapy is a safe and effective long-term treatment of the most common primary bile acid synthesis defects."( Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy.
Bernard, O; Davit-Spraul, A; Fabre, M; Gerhardt, MF; Gonzales, E; Heubi, JE; Jacquemin, E; Setchell, KD; Vincent, I, 2009
)
0.35
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
" Based on the analysis using principle components analysis (PCA), toxic groups could be distinguished from their control groups, which suggested that the variance of the contents of bile acids could evaluate hepatotoxicity caused by ET and DB."( [Evaluation on hepatotoxicity caused by Dioscorea bulbifera based on analysis of bile acids].
Chen, CC; Hu, ZB; Ji, LL; Wang, JM; Wang, ZT; Xu, Y; Yang, L, 2011
)
0.37
" From the survival and hatching experiment, no significant toxic effect was observed at AgNC concentrations of up to 200 μL/mL, and the NC-stained embryos exhibited blue fluorescence with high intensity for a long period of time, which shows that AgNCs are more stable in living system."( Sodium cholate-templated blue light-emitting Ag subnanoclusters: in vivo toxicity and imaging in zebrafish embryos.
Chandirasekar, S; Chandrasekaran, C; Muthukumarasamyvel, T; Rajendiran, N; Sudhandiran, G, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic behaviors of mixed micelles in rabbits after intravenous infusion were compared with Sandimmun."( Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A.
Chen, Y; Guo, J; Jiang, G; Ping, Q; Shen, J; Wu, T,
)
0.13
" This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rats successfully."( Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.
Liang, Q; Liu, Q; Luo, G; Pan, Y; Pang, C; Ran, X; Wang, B, 2006
)
0.33
" However, pharmacokinetic studies showed that berberine was poorly absorbed into the body so the levels of berberine in the blood and target tissues were far below the effective concentrations revealed."( A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.
Aa, J; Cao, B; Gu, S; Hylemon, PB; Li, Y; Liu, L; Paletta, JL; Radlon, JM; Ridlon, JM; Sun, R; Tang, Y; Wang, G; Wu, X; Wu, XL; Zha, W; Zhao, C; Zhou, H, 2015
)
0.42
" Furthermore, the mechanism of action of the best compound was assessed, and in silico studies to evaluate the physicochemical and pharmacokinetic properties were also conducted."( Novel steroid derivatives: synthesis, antileishmanial activity, mechanism of action, and in silico physicochemical and pharmacokinetics studies.
Calixto, SL; Coimbra, ES; da Silva Martins, J; da Silva, AD; da Trindade Granato, J; Dos Santos, JA; Prado da Silva, N, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"Detergent removal from mixed micelles was combined with preparative size exclusion chromatography (SEC) on Sephacryl S 500 HR to prepare unilamellar and spherical liposomes of defined sizes between 50 and 100 nm with a very narrow size distribution (RSD of vesicle diameter between 13% and 25%)."( Preparative size exclusion chromatography combined with detergent removal as a versatile tool to prepare unilamellar and spherical liposomes of highly uniform size distribution.
Barnert, S; Holzer, M; Momm, J; Schubert, R, 2009
)
0.35
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Moreover, more information can be provided on the evaluation of toxicity of phorate using metabonomics combined with clinical chemistry."( Metabonomics evaluation of urine from rats administered with phorate under long-term and low-level exposure by ultra-performance liquid chromatography-mass spectrometry.
Guo, L; Hou, Y; Sun, C; Sun, X; Xu, W; Zeng, Y; Zhao, X, 2014
)
0.4
" Thus, application of ursodeoxycholic acid, rosuvastatin and allopurinol in these study patients with NAFLD dosages in combination with hyperuricemia improves the clinical symptoms and normalization of biochemical parameters and normalizes the spectrum of biliary acids."( [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Barabanchyk, OV; Kozak, NP; Svintsits'kyĭ, AS, 2014
)
0.4

Bioavailability

Bile acid transporters are highly expressed both in enterocytes and hepatocytes. A transporter- recognizing prodrug strategy was applied to design and synthesize four conjugates of cytarabine with cholic acid.

ExcerptReferenceRelevance
"7 mumol/24 h, indicating an intestinal absorption rate of 77."( Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage.
Raedsch, R; Rudolph, G; Stiehl, A; Walker, S, 1992
)
0.28
" The rate of absorption of nUC, nUCG, and nUCT was one-fourth to one-half that of cholyltaurine, which served as control."( Hepatic and ileal transport and effect on biliary secretion of norursocholic acid and its conjugates in rats.
Borgström, B; Hagey, LR; Lillienau, J, 1991
)
0.28
" Purified saponins from soapwort (Saponaria officinalis), soya beans and quillaia (Quillaia saponaria) reduced the rate of absorption of the bile salt; soya-bean and soapwort saponins substantially so but quillaia saponin to a much lesser extent."( A mechanism for the hypocholesterolaemic activity of saponins.
Oakenfull, DG; Sidhu, GS, 1986
)
0.27
"Lactulose and lactitol, the synthetic compounds of lactose, are poorly absorbed from the small intestine, and both are almost exclusively metabolized by the bacterial flora of the colon."( [Lactulose and its derivatives--treatment of hepatic encephalopathy and other possible indications for its use].
Fehér, J; Prónai, L, 1993
)
0.29
" Enzyme inhibitors like bacitracin and sodium cholate noticeably enhanced the relative pharmacological bioavailability of insulin when given intratracheally with insulin to normal rats."( Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations.
Nagai, T; Shen, Z; Wei, S; Zhang, Q, 1999
)
0.3
" However, the bioavailability of unfractionated heparin (UFH) administered through the large intestine was low."( Intestinal absorption of low molecular weight heparin in animals and human subjects.
Bar-On, H; Eldor, A; Friedman, G; Hyam, E; Kidron, M; Nissan, A; Ziv, E,
)
0.13
"To study the relationship between cellular membrane fluidity and relative bioavailability (Fr) of protein and peptide drugs combined with absorption enhancers after pulmonary administration in rats."( [Study on pulmonary delivery of peptide drugs in rats: effects of absorption enhancers on cellular membrane fluidity].
Wang, ZY; Zhang, Q, 2003
)
0.32
" The relative bioavailability of mixed micelles versus Sandimmun was 112 +/- 20%, and statistical analysis demonstrated both preparations were bioequivalent."( Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A.
Chen, Y; Guo, J; Jiang, G; Ping, Q; Shen, J; Wu, T,
)
0.13
" A pharmacological bioavailability of 24."( Solid lipid nanoparticles for pulmonary delivery of insulin.
Chen, Q; Fu, H; Gong, T; He, Q; Liu, J; Wang, C; Wang, X; Zhang, Q; Zhang, Z, 2008
)
0.35
" The pharmacokinetic characteristics and bioavailability after oral administration of silybin-mixed micelles and silybin-N-methylglucamine were compared in dogs."( Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.
Cao, X; Peng, M; Qiu, H; Tong, SS; Wang, L; Xu, XM; Yu, JN; Zhu, Y, 2010
)
0.36
" After oral administration to dogs, the relative bioavailability of mixed micelles versus silybin-N-methylglucamine in dogs was 252."( Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.
Cao, X; Peng, M; Qiu, H; Tong, SS; Wang, L; Xu, XM; Yu, JN; Zhu, Y, 2010
)
0.36
"Sodium cholate/phospholipid-mixed micelles are promising carriers in orally delivery of silybin, considering their capability of enhancing bioavailability and large-scale production."( Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.
Cao, X; Peng, M; Qiu, H; Tong, SS; Wang, L; Xu, XM; Yu, JN; Zhu, Y, 2010
)
0.36
"Limited cellular uptake and low bioavailability of peptide nucleic acids (PNAs) have restricted widespread use of PNAs as antisense/antigene agents for cells in culture and not least for in vivo applications."( Nanomolar cellular antisense activity of peptide nucleic acid (PNA) cholic acid ("umbrella") and cholesterol conjugates delivered by cationic lipids.
Nielsen, PE; Shiraishi, T, 2012
)
0.38
"Curcumin (CUR) is a well-known natural compound showing antioxidant, anti-inflammatory, and antitumor abilities but characterized by poor bioavailability and chemical instability, which drastically reduce its application in the treatment of chronic diseases such as osteoarthritis."( Evaluation of monooleine aqueous dispersions as tools for topical administration of curcumin: characterization, in vitro and ex-vivo studies.
Caggia, S; Cardile, V; Cortesi, R; Crascì, L; Drechsler, M; Esposito, E; Mariani, P; Offerta, A; Panico, AM; Puglia, C, 2013
)
0.39
" In general, this research provides important information about the factors influencing the bioaccessibility of emulsified vitamin E, which could be used to design more effective emulsion-based delivery systems for increasing the oral bioavailability of this important bioactive component."( Enhancing vitamin E bioaccessibility: factors impacting solubilization and hydrolysis of α-tocopherol acetate encapsulated in emulsion-based delivery systems.
Decker, EA; McClements, DJ; Xiao, H; Yang, Y, 2015
)
0.42
" However, pharmacokinetic studies showed that berberine was poorly absorbed into the body so the levels of berberine in the blood and target tissues were far below the effective concentrations revealed."( A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.
Aa, J; Cao, B; Gu, S; Hylemon, PB; Li, Y; Liu, L; Paletta, JL; Radlon, JM; Ridlon, JM; Sun, R; Tang, Y; Wang, G; Wu, X; Wu, XL; Zha, W; Zhao, C; Zhou, H, 2015
)
0.42
" Pharmacokinetic study demonstrated that when oral administration the area under the plasma concentration-time curve (AUC0-∞) and the absolute bioavailability of paclitaxel-loaded micelles were five times greater than that of the paclitaxel solution."( Cysteine modified and bile salt based micelles: preparation and application as an oral delivery system for paclitaxel.
Fan, X; Li, L; Xu, W; Zhao, Y, 2015
)
0.42
" Bile acid transporters are highly expressed both in enterocytes and hepatocytes and to increase the oral bioavailability and investigate the potential application of cytarabine for liver cancers, a transporter- recognizing prodrug strategy was applied to design and synthesize four conjugates of cytarabine with cholic acid (CA), chenodeoxycholic acid (CDCA), hyodeoxycholic acid (HDCA) and ursodeoxycholic acid (UDCA)."( Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption.
He, Z; Li, D; Shang, L; Sun, J; Zhang, D, 2016
)
0.43
" In pharmacokinetic study, the absolute oral bioavailability of PTX loaded in hybrid liposomes had reached to 37."( The construction and characterization of hybrid paclitaxel-in-micelle-in-liposome systems for enhanced oral drug delivery.
Chen, Z; Cui, Y; Li, L; Li, Y; Zhai, G, 2017
)
0.46
" Furthermore, metabolic changes are associated with transient increase in the bioavailability of antioxidants, including lactic acid and cholic acid and anti-inflammatory metabolites 3 deoxyvitamin D3, and docosahexaenoic acid."( A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol.
Cheema, AK; Fatanmi, OO; Hinzman, CP; Mehta, KY; Singh, VK; Wise, SY; Wolff, J, 2017
)
0.46
" The oral pharmacological bioavailability of the nanoparticles in type I diabetic mice was 12."( Insulin- and cholic acid-loaded zein/casein-dextran nanoparticles enhance the oral absorption and hypoglycemic effect of insulin.
Bao, X; Qian, K; Yao, P, 2021
)
0.62
" However, the emerging GLP-1 analog peptide drugs for diabetes primarily rely on the injection route, and the development of oral dosage forms was hampered by the low oral bioavailability due to the structural vulnerability to digestive enzymes and molecule impermeability in the gastrointestinal tract."( Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery.
Bao, X; Chen, Y; Lin, L; Pan, T; Qian, K; Wang, H; Wang, Z; Xu, M; Yao, P, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" After dosing rats with 1 mmol/kg TRI in vivo the inhibition of uptake of CA and TC by subsequently isolated hepatocytes was not detected until 4 hr."( Mechanism of trichloroethylene-induced elevation of individual serum bile acids. II. In vitro and in vivo interference by trichloroethylene with bile acid transport in isolated rat hepatocytes.
Bai, CL; Stacey, NH, 1993
)
0.29
" The intensity of contraction after rectal administration of sodium caprate or sodium cholate was dependent on the concentration in the dosing solution."( A novel method for the preclinical assessment of rectal irritation.
Kinouchi, Y; Takeichi, Y; Yata, N, 1996
)
0.29
" Thus, in this work, a dose-response study was carried out to investigate the in vitro cytotoxic effect of major unconjugated and tauro- (T) or glyco- (G) conjugated bile acids and to compare this as regards their ability to inhibit DNA synthesis."( Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture.
Marin, JJ; Martinez-Diez, MC; Monte, MJ; Serrano, MA, 2000
)
0.31
"5 to 2 g/d, to our knowledge the highest dosage yet reported."( Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
Anna, M; Antonio, C; Azzaroli, F; Bovicelli, L; Colecchia, A; Constance, M; Davide, F; Enrico, R; Festi, D; Francesco, A; Giovanni, N; Giuliana, S; Luciano, B; Mazzella, G; Miracolo, A; Mwangemi, C; Nicola, R; Nigro, G; Patrizia, S; Rizzo, N; Roda, E; Simonazzi, G; Simoni, P, 2001
)
0.31
" Phospholipid (distearylphosphatidylcholine)-cholesterol-surfactant (Tween 80/sodium cholate) systems were spray-coated on beads containing cromolyn sodium and the dosage forms were characterized for vesicle formation and encapsulation efficiency."( Improved delivery of cromolyn from oral proliposomal beads.
Betageri, GV; Deshmukh, DD; Ravis, WR, 2008
)
0.35
" This information on melatonin absorption behaviors and its modulation by pharmaceutical excipients can be used in further oral dosage formulations to affect circadian rhythm."( New findings on melatonin absorption and alterations by pharmaceutical excipients using the Ussing chamber technique with mounted rat gastrointestinal segments.
Lee, BJ; Tran, HT; Tran, PH, 2009
)
0.35
"Surfactant mediated exfoliation of multilayer graphene and its effects on phenanthrene adsorption were investigated using a passive dosing technique."( Adsorption of phenanthrene on multilayer graphene as affected by surfactant and exfoliation.
Wang, Z; Xing, B; Zhao, J; Zhao, Q, 2014
)
0.4
" However, their fluid nature limited the stability of the loaded drug and hindered the development of stable oral dosage form."( Self dispersing mixed micelles forming systems for enhanced dissolution and intestinal permeability of hydrochlorothiazide.
El Maghraby, GM; El-Gizawy, SA; Osman, MA; Sultan, AA, 2017
)
0.46
" However, the emerging GLP-1 analog peptide drugs for diabetes primarily rely on the injection route, and the development of oral dosage forms was hampered by the low oral bioavailability due to the structural vulnerability to digestive enzymes and molecule impermeability in the gastrointestinal tract."( Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery.
Bao, X; Chen, Y; Lin, L; Pan, T; Qian, K; Wang, H; Wang, Z; Xu, M; Yao, P, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
trihydroxy-5beta-cholanic acid
bile acidAny member of a group of hydroxy-5beta-cholanic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration.
C24-steroidA steroid compound with a structure based on a 24-carbon (cholane) skeleton.
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
7alpha-hydroxy steroidA 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration.
12alpha-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (13)

PathwayProteinsCompounds
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761
Bile Acid Direct Signalling Pathway (1)51
Bile Acid Indirect Signalling Pathway81
Bile Acid Direct Signalling Pathway (2)32
Statin pathway03
Biochemical pathways: part I0466
Oxysterols derived from cholesterol3831

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency1.99530.794321.275750.1187AID624246
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)IC50 (µMol)100.00005.40006.10006.8000AID1802687
Vitamin D3 receptorHomo sapiens (human)IC50 (µMol)150.00000.00000.43746.4300AID1277414; AID1277417
G-protein coupled bile acid receptor 1Mus musculus (house mouse)IC50 (µMol)5.30005.30005.30005.3000AID516781
G-protein coupled bile acid receptor 1Homo sapiens (human)IC50 (µMol)6.00006.00006.00006.0000AID516780
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase A2Homo sapiens (human)Kd150.000010.000010.000010.0000AID422551
Alpha-2A adrenergic receptorHomo sapiens (human)EC50 (µMol)13.60000.00080.37336.7100AID297450
Vitamin D3 receptorHomo sapiens (human)EC50 (µMol)150.00000.00000.14232.1400AID1277413; AID1277415
Alpha-2B adrenergic receptorHomo sapiens (human)EC50 (µMol)13.60000.00051.36446.7100AID297450
Alpha-2C adrenergic receptorHomo sapiens (human)EC50 (µMol)13.60000.00050.55416.7100AID297450
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)14.63830.02372.52598.9000AID1059690; AID1798108; AID297450; AID324923; AID441573; AID673744
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
Bile acid receptorHomo sapiens (human)EC50 (µMol)81.66670.00401.419110.0000AID1351287; AID441572; AID673746
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kd150.00000.03725.018610.0000AID422551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (161)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
muscle organ developmentUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
circadian regulation of gene expressionUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
entrainment of circadian clock by photoperiodUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
locomotor rhythmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
positive regulation of mitotic cell cycleUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
circadian behaviorUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein stabilizationUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
positive regulation of interleukin-8 productionPhospholipase A2Homo sapiens (human)
positive regulation of MAP kinase activityPhospholipase A2Homo sapiens (human)
innate immune response in mucosaPhospholipase A2Homo sapiens (human)
neutrophil mediated immunityPhospholipase A2Homo sapiens (human)
fatty acid biosynthetic processPhospholipase A2Homo sapiens (human)
actin filament organizationPhospholipase A2Homo sapiens (human)
signal transductionPhospholipase A2Homo sapiens (human)
positive regulation of cell population proliferationPhospholipase A2Homo sapiens (human)
positive regulation of calcium ion transport into cytosolPhospholipase A2Homo sapiens (human)
lipid catabolic processPhospholipase A2Homo sapiens (human)
leukotriene biosynthetic processPhospholipase A2Homo sapiens (human)
antibacterial humoral responsePhospholipase A2Homo sapiens (human)
neutrophil chemotaxisPhospholipase A2Homo sapiens (human)
activation of phospholipase A2 activityPhospholipase A2Homo sapiens (human)
cellular response to insulin stimulusPhospholipase A2Homo sapiens (human)
intracellular signal transductionPhospholipase A2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPhospholipase A2Homo sapiens (human)
regulation of glucose importPhospholipase A2Homo sapiens (human)
phosphatidylcholine metabolic processPhospholipase A2Homo sapiens (human)
phosphatidylglycerol metabolic processPhospholipase A2Homo sapiens (human)
positive regulation of fibroblast proliferationPhospholipase A2Homo sapiens (human)
arachidonic acid secretionPhospholipase A2Homo sapiens (human)
positive regulation of protein secretionPhospholipase A2Homo sapiens (human)
positive regulation of immune responsePhospholipase A2Homo sapiens (human)
defense response to Gram-positive bacteriumPhospholipase A2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityPhospholipase A2Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptidePhospholipase A2Homo sapiens (human)
positive regulation of podocyte apoptotic processPhospholipase A2Homo sapiens (human)
phospholipid metabolic processPhospholipase A2Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cyclin bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
ubiquitin protein ligase bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
identical protein bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
metal ion bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
phospholipase A2 activityPhospholipase A2Homo sapiens (human)
signaling receptor bindingPhospholipase A2Homo sapiens (human)
calcium ion bindingPhospholipase A2Homo sapiens (human)
bile acid bindingPhospholipase A2Homo sapiens (human)
calcium-dependent phospholipase A2 activityPhospholipase A2Homo sapiens (human)
phospholipid bindingPhospholipase A2Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
nucleoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
centrosomeUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
membraneUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
perinuclear region of cytoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
extracellular regionPhospholipase A2Homo sapiens (human)
extracellular spacePhospholipase A2Homo sapiens (human)
cell surfacePhospholipase A2Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (201)

Assay IDTitleYearJournalArticle
AID1686034Surface tension value in 0.15 M NaCl water solution2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID388082Antifungal activity at Cryptococcus neoformans2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID486732Antimicrobial activity against Staphylococcus aureus after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID486730Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID422544Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.007 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID673745Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis relative to 10 uM LCA2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1059688Selectivity ratio of EC50 for TGR5 Y89A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID167721Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
AID490123Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID1233559Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID422547Activation of human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID388091Antiproliferative activity against HEK293 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID1852826Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID510750Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1686054Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1412043Cytotoxicity against HUVEC assessed as reduction in cell death up to 12.5 uM after 24 hrs by MTT assay2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID441589Metabolic stability in human stool broth culture assessed as 7-dehydroxylation of compound after 8 hrs2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID441574Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay relative to INT-7472009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID283564Effect on uptake of [3H]estradiol in Escherichia coli AG102 with functional AcrAB-TolC system2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID441579Metabolic stability in bile fistula rat model assessed as intact drug level recovered in bile at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1779649Agonist activity at N-terminal HA-tagged mouse TGR5 expressed in HEK293 cells assessed as reduction in intracellular cAMP levels incubated for 30 mins by Lance Ultra cAMP assay relative to control2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5
AID1059686Selectivity ratio of EC50 for TGR5 Y89F mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID441573Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID388084Antifungal activity at Yarrowia lipolytica2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID657097Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 10 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scint2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID1059690Agonist activity at wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID486729Antimicrobial activity against Escherichia coli after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID388083Antifungal activity at Benjaminiella poitrasii2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID1059678Agonist activity at TGR5 N76A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID422552Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli at 100 uM by saturation transfer difference NMR spectroscopy2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1852833Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1351287Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment after 30 mins by Alpha Screen assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID516781Agonist activity at mouse TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
AID1233570Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 20 ug/ml by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID441585Metabolic stability in bile fistula rat model assessed as intact drug level recovered in bile at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1852832Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1277420Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 18 hrs by CellTiter-Glo luminescence assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID297453Ratio of EC50 for TGR5 expressed in CHO cells to EC50 for FXR expressed in COS1 cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID441577Critical micellar concentration in 0.15 M NaCl water solution2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID167640The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 25%1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Specific inhibitors of ileal bile acid transport.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID441580Metabolic stability in bile fistula rat model assessed as conjugated drug level recovered in bile at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID516780Agonist activity at human TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
AID510747Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID441578Binding affinity to albumin2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1059684Agonist activity at TGR5 N93A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID283561Effect on modulation in uptake of [3H]progesterone in Escherichia coli AG102 with marR1 mutation2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1415895Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation cou2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID1810243Effect on mouse GABA receptor expressed in mouse C-low-threshold mechanoreceptors DRG neurons at 10 uM
AID441575Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay relative to lithocholic acid2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1277415Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1852831Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID54340Binding constant towards cyclodextrin conjugated peptide (with pyrene) at 25 degrees Centigrade2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Fluorescence resonance energy transfer in a novel cyclodextrin-peptide conjugate for detecting steroid molecules.
AID441576Solubility in 0.1M HCl water solution2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1686036Binding affinity to human serum albumin2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1059692Selectivity ratio of EC50 for TGR5 N93A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1686032Solubility in water measured for protonated species2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID657096Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scin2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID1686059Drug metabolism in bile of fistula Wistar-Han rat model assessed as taurine conjugate formation at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1277414Antagonist activity against VDR-LBD (unknown origin) expressed in Escherichia coli assessed as inhibition of VDR agonist LG190178-induced SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID441586Metabolic stability in bile fistula rat model assessed as conjugated drug level recovered in bile at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID167719Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
AID297450Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID441581Cholerectic effect in bile fistula rat model assessed as maximum bile secretion rate at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID510748Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID263154Induction of HIV1 NL4-3 virus replication in CEM-GFP cells2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Amino functionalized novel cholic acid derivatives induce HIV-1 replication and syncytia formation in T cells.
AID388081Antifungal activity at Candida albicans2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID1059685Selectivity ratio of EC50 for TGR5 S270A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1686057Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion of the administered compound including the secreted taurine conjugates at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID673746Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID486734Antimicrobial activity against Bacillus megaterium after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID1233569Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 100 ug/ml by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1686058Drug metabolism in bile of fistula Wistar-Han rat model assessed as taurine conjugate formation at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1277413Agonist activity at VDR-LBD (unknown origin) expressed in Escherichia coli assessed as SRC2-3 coactivator peptide recruitment after 30 mins by fluorescence polarization assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID422543Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.03 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID490121Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID1810241Effect on mouse GABA receptor expressed in mouse peptidergic nociceptive DRG neurons at 10 uM
AID1233565Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 100 ug/ml by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1412073Cytotoxicity against HUVEC assessed as reduction in cell viability at 6.25 to 100 uM after 24 hrs by MTT assay2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID422554Agonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to control2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID486733Antimicrobial activity against Enterococcus faecalis after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID1686060Drug metabolism in bile of fistula Wistar-Han rat model assessed as area under the curve of the biliary concentration corrected for the bile volume at 60 umol/kg, iv measured at 4 hrs by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1069888Hemolytic activity in human erythrocytes assessed as increase in cell permeability up to 1 mg/mL after 60 mins2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis and haemolytic activity of novel salts made of nicotine alkaloids and bile acids.
AID388087Antibacterial activity at Staphylococcus aureus2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1686055Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID441584Cholerectic effect in bile fistula rat model assessed as maximum bile acids secretion rate per kg body weight at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID662694Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N at 10 uM by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID1059679Agonist activity at TGR5 S270A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1412063Antiangiogenic activity in Tg(fli:eGFP) zebrafish embryo assessed as effect on phynotypic changes at 6.25 to 12.5 uM after 72 hrs post fertilization by fluorescence microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1686061Drug metabolism in bile of fistula Wistar-Han rat model assessed as area under the curve of the biliary concentration corrected for the bile volume at 60 umol/kg, ID measured at 4 hrs by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID441583Cholerectic effect in bile fistula rat model assessed as maximum bile secretion rate at 1 umol/min/kg administered intraduodenally over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1686052Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum bile secretion at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID490122Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID441582Cholerectic effect in bile fistula rat model assessed as maximum bile acids secretion rate per kg body weight at 1 umol/min/kg, iv over 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID1277417Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites.
AID1686053Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum bile secretion at 60 umol/kg, ID by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID422551Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli by resonance energy transfer assay in presence of trimethyl-ammonium-diphenylhexatriene2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1412050Antiangiogenic activity in HUVEC assessed as inhibition of endothelial tube formation at 25 uM after overnight incubation by inverted microscopic analysis2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID1779650Agonist activity at N-terminal HA-tagged dog TGR5 expressed in HEK293 cells assessed as reduction in intracellular cAMP levels incubated for 30 mins by Lance Ultra cAMP assay relative to control2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5
AID1412040Toxicity in zebrafish embryo assessed as reduction in embryo survival up to 50 uM2017MedChemComm, Dec-01, Volume: 8, Issue:12
Deciphering the role of hydrophobic and hydrophilic bile acids in angiogenesis using
AID297451Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1810242Effect on mouse GABA receptor expressed in mouse non-peptidergic nociceptive DRG neurons at 10 uM
AID1233553Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID422553Binding affinity to pig PLA2 at 100 uM by saturation transfer difference NMR spectroscopy2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1233567Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 100 ug/ml by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID1779646Agonist activity at N-terminal HA-tagged human TGR5 expressed in HEK293 cells assessed as reduction in intracellular cAMP levels incubated for 30 mins by Lance Ultra cAMP assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5
AID1810244Effect on mouse GABA receptor expressed in mouse DRG neurons at 10 uM using cold thermosensors
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1686056Drug metabolism in bile of fistula Wistar-Han rat model assessed as maximum biliary secretion of the administered compound including the secreted taurine conjugates at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID1852829Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID167720Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
AID1247196Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition at 3 ug/ml by XRMA method relative to control2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.
AID422555Antagonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to chenodeoxycholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID388085Antifungal activity at Fusarium oxysporum2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID1686033Critical micelle concentration in 0.15 M NaCl water solution2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1686039Stability in bile of fistula Wistar-Han rat model assessed as drug recovery of unmodified compound at 60 umol/kg, iv by HPLC-ES-MS/MS analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID441572Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID673747Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs relative to 10 uM CDCA2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID510749Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID388086Antibacterial activity at Escherichia coli2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID1059689Selectivity ratio of EC50 for TGR5 E169A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID165385The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 75%1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Specific inhibitors of ileal bile acid transport.
AID16860351-octanol-water partition coefficient, logP of compound as ionized species2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID283565Effect on uptake of [3H]estradiol in Escherichia coli CE1 with functional AcrAB-TolC system2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1059683Agonist activity at TGR5 E169A mutant (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID388089Antibacterial activity at Escherichia coli assessed as concentration required to lower the MIC of erythromycin from 64 to 1 ug/mL after 24 hrs2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID486731Antimicrobial activity against Enterobacter aerogenes after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID673748Critical micelle concentration of the compound in 0.15 M NaCl water solution2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID388088Antifungal activity at Candida albicans assessed as concentration required to lower the MIC of fluconazole from 32 to 1 ug/mL after 48 hrs2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID1233566Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 20 ug/ml by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID673744Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1247194Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition at 30 ug/ml by XRMA method relative to control2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.
AID54341Sensitivity value towards cyclodextrin conjugated peptide (with pyrene) at 25 degrees Centigrade2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Fluorescence resonance energy transfer in a novel cyclodextrin-peptide conjugate for detecting steroid molecules.
AID673751Binding affinity to albumin by equilibrium dialysis2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1852828Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1351288Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment after 30 mins by Alpha Screen assay relative to CDCA2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: Novel insights into bile acid signalling and detoxification.
AID1247195Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition at 10 ug/ml by XRMA method relative to control2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.
AID1233552Cytotoxicity against human WI38 cells by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID388090Antiproliferative activity against human MCF7 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID441588Metabolic stability in human stool broth culture assessed as 7-dehydroxylation of compound after 1 hr2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
AID165380The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 50%1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Specific inhibitors of ileal bile acid transport.
AID510559Antibacterial activity against Escherichia coli AG102MB2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1233568Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 20 ug/ml by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID673750Aqueous solubility of the compound in 0.1 M HCl water at pH 3 by HPLC-ES-MS/MS2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID6737491-Octanol/water partition coefficient, log P of the compound by conventional shake-flask method2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.
AID1069886Hemolytic activity in human erythrocytes assessed as release of hemoglobin at 0.75 mg/mL after 60 mins relative to control2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis and haemolytic activity of novel salts made of nicotine alkaloids and bile acids.
AID657095Restoration of wild type human BSEP trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as decrease in [3H]taurocholate accumulation at 10 to 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID490124Lipophilicity, log P of the compound2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID297449Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay relative to lithocholic acid2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1059687Selectivity ratio of EC50 for TGR5 N76A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Probing the Binding Site of Bile Acids in TGR5.
AID1852825Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID297452Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay relative to 6ECDCA2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1852830Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1852827Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Design and synthesis of bile acid derivatives and their activity against colon cancer.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1802687Di-UB K63-2 Hydrolysis Assay from Article 10.1016/j.chembiol.2017.03.002: \\Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G0/G1 Arrest by Inhibiting Deubiquitinase USP2a.\\
AID1798108TGR5 Activity Assay from Article 10.1021/jm070633p: \\Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.\\2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
AID1346437Human GPBA receptor (Bile acid receptor)2002Biochemical and biophysical research communications, Nov-15, Volume: 298, Issue:5
Identification of membrane-type receptor for bile acids (M-BAR).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,854)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990453 (24.43)18.7374
1990's421 (22.71)18.2507
2000's385 (20.77)29.6817
2010's456 (24.60)24.3611
2020's139 (7.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 93.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index93.46 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index161.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (93.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (1.92%)5.53%
Trials0 (0.00%)5.53%
Reviews29 (1.51%)6.00%
Reviews0 (0.00%)6.00%
Case Studies22 (1.14%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,837 (95.43%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]